Vor Biopharma Inc. (VOR) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0875K2M3M4M4M5M6M7MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
050M100M150M200M250M300M350M400MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EBITDA

EBITDA
-300M-262M-225M-187M-150M-112M-75M-37M1Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
0112225338450562675788900Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-90-79-67-56-44-33-22-101Q4 2024

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
01252503755006257508751KQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Price-to-Earning Ratio

P/E Ratio
-1-1-0-000011Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0375K750K1M2M2M2M3M3MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000111222Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
012346789Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
038M75M112M150M188M225M262M300MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
038M75M112M150M188M225M262M300MQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025
🏦 Balance Sheet
📈 Key Metrics